Lercanidipine Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10mg, 20mg
Reference Brands: Zanidip (EU/UK), Lercadip (EU/UK)
Category:
Heart Disorder
Lercanidipine is a calcium channel blocker (dihydropyridine class) used primarily for the treatment of hypertension (high blood pressure). It works by relaxing and widening blood vessels, allowing blood to flow more easily and reducing the workload on the heart.
Lercanidipine helps prevent complications associated with high blood pressure such as heart attacks, strokes, and kidney damage. It has a long duration of action and is typically administered once daily.
Lercanidipine is available in Tablets
and strengths such as 10mg, 20mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lercanidipine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lercanidipine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing